Sirnaomics, Inc., a leading privately held biopharmaceutical company for discovery and development of RNAi therapeutics, is a Delaware corporation headquartered in Gaithersburg, Maryland, USA, with subsidiaries in Suzhou and Guangzhou, China. The company is pursuing the mission of advancing its proprietary technologies using pluripotent siRNA cocktail design and nanoparticle-enhanced therapeutic delivery to treat critical human diseases. Members of the senior management team bring over 100 years of combined experience in the biopharmaceutical, financial, clinical and business management in both USA and China. Supported with funding from private investors, corporate partnerships and government grants, Sirnaomics has developed a strong portfolio of intellectual properties with an enriched product pipeline. The therapeutic areas of interest include anti-fibrotic medicine, cancer therapeutics, and others.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 05/04/16 | $10,000,000 | Series B |
Value Measured Investment | undisclosed |
| 06/06/18 | $25,000,000 | Series C-1 |
HuaKong Equity Investment Qianhai Shenghui Investment Sangel Capital Yuexiu New Industrial Investment  | undisclosed |
| 04/26/19 | $22,000,000 | Series C-2 |
CR-CP Life Sciences Fund Legend Sky Investment Rich Yield Capital Rolling Boulder Investment | undisclosed |
| 10/26/20 | $105,000,000 | Series D |
Alpha Win Capital HongTao Capital Longmen Capital Rotating Boulder Fund Sangel Capital Sunshine Riverhead Capital Walvax Biotechnology | undisclosed |
| 07/01/21 | $105,000,000 | Series E |
Rotating Boulder Fund | undisclosed |
